<SEC-DOCUMENT>0001193125-24-053592.txt : 20240229
<SEC-HEADER>0001193125-24-053592.hdr.sgml : 20240229
<ACCEPTANCE-DATETIME>20240229165525
ACCESSION NUMBER:		0001193125-24-053592
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20240229
FILED AS OF DATE:		20240229
DATE AS OF CHANGE:		20240229

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Theratechnologies Inc.
		CENTRAL INDEX KEY:			0001512717
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A8
		FISCAL YEAR END:			1130

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35203
		FILM NUMBER:		24704739

	BUSINESS ADDRESS:	
		STREET 1:		2015 PEEL STREET
		STREET 2:		5TH FLOOR
		CITY:			MONTREAL
		STATE:			A8
		ZIP:			H3A 1T8
		BUSINESS PHONE:		514-336-7800

	MAIL ADDRESS:	
		STREET 1:		2015 PEEL STREET
		STREET 2:		5TH FLOOR
		CITY:			MONTREAL
		STATE:			A8
		ZIP:			H3A 1T8
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d755797d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C.&nbsp;20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Report of
Foreign Private Issuer </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Rule <FONT STYLE="white-space:nowrap">13a-16</FONT> or
<FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>under the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>February&nbsp;29, 2024 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number <FONT STYLE="white-space:nowrap">001-35203</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>THERATECHNOLOGIES INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2015 Peel
Street, Suite 1100 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Montr&eacute;al, Qu&eacute;bec, Canada </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>H3A 1T8 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of
principal executive offices) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form
<FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT STYLE="white-space:nowrap">40-F:</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
<FONT STYLE="white-space:nowrap">20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form</FONT> <FONT STYLE="white-space:nowrap">40-F&#8194;&#9744;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by
Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&#8194;&#9744;&#8195;&#8195;&#8195;No&#8194;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Note: Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1) only permits the submission in paper of a Form <FONT
STYLE="white-space:nowrap">6-K</FONT> if submitted solely to provide an attached annual report to security holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check
mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&#8194;&#9744;&#8195;&#8195;&#8195;No&#8194;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Note: Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7) only permits the submission in paper of a Form <FONT
STYLE="white-space:nowrap">6-K</FONT> if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or
legally organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home country exchange on which the registrant&#146;s securities are traded, as long as the report or other document is not a press release, is not required
to be and has not been distributed to the registrant&#146;s security holders, and, if discussing a material event, has already been the subject of a Form <FONT STYLE="white-space:nowrap">6-K</FONT> submission or other Commission filing on EDGAR.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the
information to the Commission pursuant to Rule <FONT STYLE="white-space:nowrap">12g3-2(b)</FONT> under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&#8194;&#9744;&#8195;&#8195;&#8195;No&#8194;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicate below the file number assigned to the registrant in connection with Rule
<FONT STYLE="white-space:nowrap">12g3-2(b):</FONT> <FONT STYLE="white-space:nowrap">82-______________.</FONT> </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>THERATECHNOLOGIES INC. </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release Dated February&nbsp;29, 2024.</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THERATECHNOLOGIES INC.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jocelyn Lafond</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jocelyn Lafond</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">General Counsel and Corporate Secretary</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: February&nbsp;29, 2024 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d755797dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g755797g0301023548008.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>THERATECHNOLOGIES ANNOUNCES THE RESIGNATION OF ONE OF ITS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>DIRECTORS, MR.&nbsp;ALAIN TRUDEAU </B></P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify"><B>Montreal, Canada &#150; February</B><B><U></U></B><B>&nbsp;29, 2024</B> &#150; Theratechnologies Inc. (&#147;Theratechnologies&#148; or the
&#147;Company&#148;) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Mr.&nbsp;Alain Trudeau has resigned from the Board of Directors of
Theratechnologies and as a member of its Audit Committee, effective immediately. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">&#147;I want to thank Alain for his contributions to
Theratechnologies as a director since joining the Company in October 2020 and for completing the annual review for the 2023 fiscal year&#148;, said Dawn Svoronos, Chair of the Board at Theratechnologies. &#147;Alain was the current Chair of the
Audit Committee and, during his tenure as a Board member, he was also a member of the Compensation Committee from May 2021 until March 2023.&#148; </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Consistent with past practices, the Board of Directors of the Company will assess whether it will appoint a new member to fill this vacancy at the Board
before the next annual meeting of shareholders. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">The Board has appointed Frank Holler as Chair of the Audit Committee and plans to appoint a new
independent director to this committee in order to ensure compliance with securities regulation. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>About Theratechnologies </B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies
addressing unmet medical needs. Further information about Theratechnologies is available on the Company&#146;s website at <U>www.theratech.com</U>, on SEDAR<B>+</B> at www.sedarplus.ca and on EDGAR at <U>www.sec.gov</U>. Follow Theratechnologies on
<U>LinkedIn</U>&nbsp;and&nbsp;<U>X</U> (formerly Twitter). </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>Forward-Looking Information </B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">This press release contains forward-looking statements and forward-looking information (collectively, &#147;Forward-Looking Statements), within the
meaning of applicable securities laws, that are based on our management&#146;s beliefs and assumptions and on information currently available to our management. You can identify Forward-Looking Statements by terms such as &#147;may&#148;,
&#147;will&#148;, &#147;should&#148;, &#147;could&#148;, &#147;would&#148;, &#147;outlook&#148;, &#147;believe&#148;, &#147;plan&#148;, &#147;envisage&#148;, &#147;anticipate&#148;, &#147;expect&#148; and &#147;estimate&#148;, or the negatives of
these terms, or variations of them. The Forward-Looking Statements contained in this press release include, but are not limited to, statements regarding the assessment by the Board of Directors of the Company about the appointment of a new member to
the board. Although the Forward-Looking Statements contained in this press release are based upon what the Company believes are reasonable assumptions in light of the information currently available, investors are cautioned against placing undue
reliance on these </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">
statements since actual results may vary from the Forward-Looking Statements. Forward-Looking Statements assumptions are subject to a number of risks and uncertainties, many of which are beyond
Theratechnologies&#146; control that could cause actual results to differ materially from those that are disclosed in or implied by such Forward-Looking Statements. We refer current and potential investors to the &#147;Risk Factors&#148; section of
our Form <FONT STYLE="white-space:nowrap">20-F</FONT> dated February<U></U>&nbsp;21, 2024 available on SEDAR+ at <U>www.sedarplus.ca</U> and on EDGAR at <FONT STYLE="font-family:ARIAL; font-size:11pt" COLOR="#0563c1"><U>www.sec.gov</U></FONT><FONT
STYLE="font-family:ARIAL"> under Theratechnologies&#146; public filings for additional risks related to the Company. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on
Forward-Looking Statements. Forward-Looking Statements reflect current expectations regarding future events and speak only as of the date of this press release and represent our expectations as of that date. We undertake no obligation to update or
revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise, except as may be required by applicable law. </FONT></P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>Contacts: </B></P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Investor inquiries: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Philippe Dubuc </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Senior Vice President and Chief
Financial Officer </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify"><FONT STYLE="font-family:ARIAL; font-size:11pt" COLOR="#0563c1"><U>pdubuc@theratech.com</U></FONT><FONT STYLE="font-family:ARIAL">
</FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-438-315-6608</FONT></FONT></FONT> </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Media inquiries: </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Julie Schneiderman </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Senior Director, Communications&nbsp;&amp; Corporate Affairs </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify"><FONT STYLE="font-family:ARIAL; font-size:11pt" COLOR="#0563c1"><U>communications@theratech.com</U></FONT><FONT STYLE="font-family:ARIAL"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-514-336-7800</FONT></FONT></FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">2 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g755797g0301023548008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g755797g0301023548008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !$ *,# 2(  A$! Q$!_\0
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M>'M8\-WFFV4=Q=SW";(PT)55/9N>XZ\5N_"W2+W2?";"^B>%[F=IDB<895(
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
#?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
